Cited 0 times in
Comparison of the Pharmacokinetics of CT-P13 Between Crohn's Disease and Ulcerative Colitis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 천재영 | - |
dc.date.accessioned | 2024-01-03T01:01:18Z | - |
dc.date.available | 2024-01-03T01:01:18Z | - |
dc.date.issued | 2023-07 | - |
dc.identifier.issn | 0192-0790 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/197432 | - |
dc.description.abstract | Background: We aimed to compare trough infliximab levels and the development of antidrug antibody (ADA) for 1 year between Crohn's disease (CD) and ulcerative colitis (UC) patients who were biologic-naive, and to evaluate their impact on clinical outcomes. Methods: This was a prospective, multicenter, observational study. Biologic-naive patients with moderate to severe CD or UC who started CT-P13, an infliximab biosimilar, therapy were enrolled. Trough drug and ADA levels were measured periodically for 1 year after CT-P13 initiation. Results: A total of 267 patients who received CT-P13 treatment were included (CD 168, UC 99). The rates of clinical remission (72% vs. 32.3%, P <0.001) at week 54 were significantly higher in CD than in UC. The median trough drug level (μg/mL) was significantly higher in CD than in UC up to week 14 (week 2, 18.7 vs. 14.7, P <0.001; week 6, 12.5 vs. 8.6, P <0.001; week 14, 3.4 vs. 2.5, P =0.001). The median ADA level (AU/mL) was significantly lower in CD than in UC at week 2 (6.3 vs. 6.5, P =0.046), week 30 (7.9 vs. 11.8, P =0.007), and week 54 (9.3 vs. 12.3, P =0.032). Development of ADA at week 2 [adjusted odds ratio (aOR)=0.15, P =0.026], initial C-reactive protein level (aOR=0.87, P =0.032), and CD over UC (aOR=1.92, P <0.001) were independent predictors of clinical remission at week 54. Conclusion: Infliximab shows more favorable pharmacokinetics, including high drug trough and low ADA levels, in CD than in UC, which might result in better clinical outcomes for 1-year infliximab treatment in CD patients. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Wolters Kluwer Health, Inc. | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL GASTROENTEROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Biosimilar Pharmaceuticals* / therapeutic use | - |
dc.subject.MESH | Colitis, Ulcerative* / chemically induced | - |
dc.subject.MESH | Colitis, Ulcerative* / drug therapy | - |
dc.subject.MESH | Crohn Disease* / drug therapy | - |
dc.subject.MESH | Gastrointestinal Agents / therapeutic use | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infliximab / therapeutic use | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Remission Induction | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Comparison of the Pharmacokinetics of CT-P13 Between Crohn's Disease and Ulcerative Colitis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Eun Soo Kim | - |
dc.contributor.googleauthor | Sung Kook Kim | - |
dc.contributor.googleauthor | Dong Il Park | - |
dc.contributor.googleauthor | Hyo Jong Kim | - |
dc.contributor.googleauthor | Yoo Jin Lee | - |
dc.contributor.googleauthor | Ja Seol Koo | - |
dc.contributor.googleauthor | Eun Sun Kim | - |
dc.contributor.googleauthor | Hyuk Yoon | - |
dc.contributor.googleauthor | Ji Hyun Lee | - |
dc.contributor.googleauthor | Ji Won Kim | - |
dc.contributor.googleauthor | Sung Jae Shin | - |
dc.contributor.googleauthor | Hyung Wook Kim | - |
dc.contributor.googleauthor | Hyun-Soo Kim | - |
dc.contributor.googleauthor | Young Sook Park | - |
dc.contributor.googleauthor | You Sun Kim | - |
dc.contributor.googleauthor | Tae Oh Kim | - |
dc.contributor.googleauthor | Jun Lee | - |
dc.contributor.googleauthor | Chang Hwan Choi | - |
dc.contributor.googleauthor | Dong Soo Han | - |
dc.contributor.googleauthor | Jaeyoung Chun | - |
dc.contributor.googleauthor | Hyun Soo Kim | - |
dc.contributor.googleauthor | IBD Research Group in the Korean Association for the Study of Intestinal Diseases | - |
dc.identifier.doi | 10.1097/mcg.0000000000001715 | - |
dc.contributor.localId | A05701 | - |
dc.relation.journalcode | J01319 | - |
dc.identifier.eissn | 1539-2031 | - |
dc.identifier.pmid | 35470308 | - |
dc.identifier.url | https://journals.lww.com/jcge/fulltext/2023/07000/comparison_of_the_pharmacokinetics_of_ct_p13.10 | - |
dc.contributor.alternativeName | Cheon, Jae Young | - |
dc.contributor.affiliatedAuthor | 천재영 | - |
dc.citation.volume | 57 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 601 | - |
dc.citation.endPage | 609 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL GASTROENTEROLOGY, Vol.57(6) : 601-609, 2023-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.